US 11,866,513 B2
Anti-TMPRSS6 antibodies and uses thereof
Xin Du, La Jolla, CA (US); Buxin Chen, San Marcos, CA (US); and Yu Jean Wang, San Diego, CA (US)
Assigned to MABWELL THERAPEUTICS, INC., La Jolla, CA (US)
Filed by MABWELL THERAPEUTICS INC., La Jolla, CA (US)
Filed on Jun. 5, 2023, as Appl. No. 18/329,172.
Application 18/329,172 is a continuation of application No. 17/916,008, previously published as PCT/US2021/025775, filed on Apr. 5, 2021.
Claims priority of provisional application 63/158,265, filed on Mar. 8, 2021.
Claims priority of provisional application 63/006,695, filed on Apr. 7, 2020.
Prior Publication US 2023/0348623 A1, Nov. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/40 (2006.01); A61P 7/06 (2006.01); C12N 15/63 (2006.01)
CPC C07K 16/40 (2013.01) [A61P 7/06 (2018.01); C12N 15/63 (2013.01); C07K 2317/565 (2013.01)] 25 Claims
 
1. An anti-type II transmembrane serine protease 6 (TMPRSS6) antibody comprising: a heavy chain complementarity-determining region 1 (HC CDR1) comprising the amino acid sequence of SEQ ID NO: 52, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 53, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 54; and a light chain complementarity-determining region 1 (LC CDR1) comprising the amino acid sequence of SEQ ID NO: 57, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 58, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 59.